cyrilzakka/clinical-trials huggingface dataset:
A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers

The purpose of this study is to evaluate the Pharmacokinetics and safety of Azilsartan Trimethylethanolamine in healthy volunteers


Eligibility Criteria:
Inclusion Criteria:

* Healthy males or females
* Aged from 18 years to 45 years
* Body mass index (BMI) 19 to 25kg/m2

Exclusion Criteria:

* Has a known sensitivity to angiotensin II receptor blocker（ARB）
* With evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the investigator or medical monitor
* Has known or suspected history of alcoholism or drug abuse or misuse
* With a history of laboratory results that show the presence of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV)
* Pregnant,lactating，menstrual
* Vegetarian
* Postural hypotension
* Systolic blood pressure\<100mmHg，or\>130mmHg;and/or diastolic blood pressure\<70mmHg,or\>90mmHg
Efficacy of Different Anesthesia Methods in Transbronchial Biopsy

This study investigates the efficacy of different anesthesia methods (general anesthesia with laryngeal mask airway and local nebulized anesthesia) for transbronchial biopsy using an electronic bronchoscope. The study retrospectively analyzed cases of transbronchial biopsy performed at the Respiratory Endoscopy Center of Sichuan Provincial People's Hospital from June 5, 2020, to June 5, 2024. Data collected included age, gender, primary diagnosis, anesthesia method, biopsy method, operation time (excluding general anesthesia and laryngeal mask airway placement time), lesion location and size, pathological results, and follow-up status.

General anesthesia and local anesthesia are the primary anesthesia methods for interventional respiratory endoscopy. While general anesthesia offers greater comfort, it carries anesthesia-related risks. Local anesthesia, on the other hand, provides a relatively low surgical risk and cost-effectiveness. However, there is limited research on whether its diagnostic value is inferior to that of general anesthesia.This study investigates the efficacy of the two anesthesia methods (general anesthesia with laryngeal mask airway and local nebulized anesthesia) for transbronchial biopsy. The study retrospectively analyzed cases of transbronchial biopsy performed at the Respiratory Endoscopy Center of Sichuan Provincial People's Hospital from June 5, 2020, to June 5, 2024. Data collected included age, gender, primary diagnosis, anesthesia method, biopsy method(forcep/cryobiopsy), operation time (excluding general anesthesia and laryngeal mask airway placement time), lesion location and size, pathological results, and follow-up status(pneumothorax、hemorrhage).

Eligibility Criteria:
Inclusion Criteria:

* Completed Transbronchial Biopsy；the platelets count and PT, APTT tests were normal, normal ECG, Anesthesiologist evaluation was needed in General anesthesia group.

Exclusion Criteria:

* patients with contraindication of bronchoscopy (such as respiratory failure and acute cardio-cerebrovascular events), and women who were pregnant.
Effects of Remote Ischemic Conditioning on Blood Pressure in Older Patients With Hypertension

The purpose of this study is to learn about effects of remote ischemic conditioning on blood pressure in older patients with essential hypertension.

Current studies have shown that remote ischemic conditioning can improve vascular endothelial function and inhibit sympathetic nervous system activity. Thus it may provide some organ protection as well as anti-hypertensive effects. The purpose of this study is to learn about effects of remote ischemic conditioning on blood pressure in older patients with essential hypertension.

Eligibility Criteria:
Inclusion Criteria:

* 1) Age ≥65 years and ≤85 years, regardless of gender;
* 2) History of essential hypertension and clinical systolic blood pressure ≥ 140 mmHg, regardless of whether they are receiving antihypertensive medication;
* 3) Willing to participate and sign the informed consent.

Exclusion Criteria:

* 1) Secondary hypertension;
* 2) Clinical blood pressure ≥ 180/110 mmHg or 24-hour mean arterial pressure ≥ 170/100 mmHg;
* 3) Severe organ dysfunction or failure;
* 4) Severe hematologic disorders or significant coagulation abnormalities;
* 5) History of atrial fibrillation or myocardial infarction within 6 months;
* 6) Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
* 7) Individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc;
* 8) Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment;
* 9) Other conditions that the researchers think are not suitable for the project.
Effect of Short-term Oxygen During CPET in HFpEF

In a randomized, sham-controlled crossover trial the investigators will test whether supplemental oxygen given during cardiopulmonary exercise testing will improve exercise performance and physiological parameters in patients with heart failure with preserved ejection fraction.


Eligibility Criteria:
Inclusion Criteria:

* HFpEF, stable medication for at least 4 weeks.

Exclusion Criteria:

* instable status, pregnancy, clinically relevant concomitant diseases, inability to follow the study procedures
Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma


Eligibility Criteria:
* Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic disease.
* All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA type A1, A2, or B35.
* Patients must have adequate organ function and an estimated life expectancy of at least 3 months.
Outcome of Transcatheter Closure of Patent Ductus Arteriosus in Pediatric Cardiology Unit in 3 Years Duration

Transcatheter Closure of Patent Ductus Arteriosus to evaluate the outcome of percutaneous transcatheter closure of patent ductus arteriosus in children


Eligibility Criteria:
Inclusion Criteria:

* Children with Patent Ductus Arteriosus confirmed by echocardiography
* aged from 6 months to 16 years underwent percutaneous transcatheter PDA closure at Pediatric Cardiology Unit.

Exclusion Criteria:

* Children with PDA younger than 6 months or older than 16 years and that are not candidate for transcatheter closure .
The Role That Peroral Endoscopic Myotomy (POEM) Could Play in the Treatment of Achalasia

Based on the work of the Doctors at the Mayo Clinic Rochester, a new technique for a less invasive treatment for Achalasia has been developed.

The purpose of this study is to decide the role this less invasive treatment (Peroral Endoscopic Myotomy) has in the treatment of patient's with achalasia.


Eligibility Criteria:
Inclusion Criteria:

* Patients between the ages of 18 and 80 with achalasia diagnosed by a combination of compatible symptoms, barium esophagography and high resolution manometry.

Exclusion Criteria:

* Patients who are poor surgical risks, have had previous treatment for achalasia or esophageal or gastric surgery, have an epiphrenic diverticulum or are unwilling to be followed in the protocol.
* Female patients are eligible if they are NOT pregnant or lactating AND ne of the following criteria is met:
* The patient is surgically sterile (by means of hysterectomy/bilateral tubal ligation)
* The patient is at least one year postmenopausal (no menses for 12 months).
* The patient is using a highly effective method of contraception, if childbearing potential, AND has a negative urine human chorionic gonadotropin beta subunit (ß HCG) pregnancy test result during Screening, and prior to trial drug administration.
* Highly effective methods of birth control are defined as those which result in a low failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner.
* Withdrawal, single- or double barrier methods (including condoms) and rhythm methods are NOT ACCEPTABLE methods of contraception for the purposes of this clinical trial due to the high incidence of contraceptive failures with these methods.
* Vulnerable populations, such as those with diminished mental acuity, will be excluded.
Changing Diabetes® World Tour

This study is conducted in the Middle East, Northern Africa and Europe. The aim of this study is to contribute to the design of a simple screening strategy for countries in scope, by exploring the association between risk factors and undiagnosed diabetes in a screening study.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent obtained

Exclusion Criteria:

* Subjects with known diabetes (exception: women with a history of gestational diabetes should not be excluded)
* Pregnant women or women who have given birth within less than a month
* Subjects suffering from severe illness
* Subjects with the inability to read and understand the information given (either due to illiteracy or vision problems) and therefore unable to give an informed consent
* Subjects with mental impairment
* Subjects treated with systemic cortico-steroids
Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy

This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric Hypertrophy.

Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will be intramuscularly injected with the study drug or the placebo to find appropreate dose for the treatment of Benign Masseteric Hypertrophy. Thereafter, follow-up visits will be made and efficacy and safety assessment will be conducted.

Eligibility Criteria:
Inclusion Criteria:

1. Subject who shows benign masseteric hypertrophy
2. Male or female subject over 19 years of age and written informed consent is obtained from the patient or LAR.
3. Subject who has bisymmetry of masster at visual assessment.
4. Subejects who qualifies the standard meets on ultrasonics wave value.
5. Subjects who can and will comply with the requirements of the protocol.

Exclusion Criteria:

1. Diagnosis of myasthenia, facial palsy or severe facial asymmetry
2. Subject who got any treatment, including double jaw surgery, laser, thread treatment etc. in 1 year.
3. Subject who had previously received botulinum toxin within 3 months prior to the study entry
4. Subject who is participating in other investigational study at present or 30 prior to the screening date.
5. Subject with known hypersensitivity to botulinum toxin
6. Subject who are pregnant or lactating or found pregnancy though the urine or sebum test or disagreed to avoid pregnancy during study preiod.
7. Subjects who are not eligible for this study at the discretion of the investigator.
Mentored Community Gardening for Individuals With Skin Cancer

The investigators will conduct a single-arm pilot feasibility trial of mentored community gardening for melanoma survivors integrating dosimeters and accelerometers. Harvest for Health Together Arizona (H4H2-AZ) is an evidence-based program adapted for arid desert gardening that also addresses sun safety through group workshops and peer education. The primary aim is to evaluate adherence to the intervention.

In collaboration with Banner Health, University of Arizona Cancer Center, Community Gardens of Tucson, and UArizona Pima County Cooperative Extension Master Gardeners, the investigators will conduct a pilot feasibility study of community gardening in melanoma survivors integrating UV sensors. Harvest for Health Together Arizona (H4H2-AZ) is an evidence-based program adapted for arid desert gardening that also addresses sun safety through experiential workshops and education. The investigators propose to evaluate adherence to and acceptability of the intervention. The investigators aim to see if H4H2-AZ may improve cancer preventive health behaviors (including diet, physical activity, energy balance, and UV protection) and quality of life among melanoma survivors.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older at their last birthday \& in good general health.
* Clinical diagnosis of skin cancer (including in situ).
* Has access to a phone or tablet with a camera and internet.
* Currently living in Pima County Arizona.
* Ability to understand and speak English.
* Ability to provide written informed consent document.
* Ability to physically participate in gardening activities (including kneeling, sitting, bending, and carrying up to 10 pounds) with or without the use of mobility assistive devices.

Exclusion Criteria:

* Currently immunosuppressed by virtue of medication or disease.
* Has a diagnosed and uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction

This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.

Eligible patients to be recruited will have scheduled upcoming senile cataract surgery. Enrolled patients in the active arm (n=25) will receive pre-operative Systane iLux treatment two weeks prior to surgery at the baseline visit. Patients in the control arm will receive no Systane iLux treatment at the baseline visit two weeks prior to cataract surgery. Patients will be assessed on baseline metrics for dry eye disease stemming and meibomian gland dysfunction (MGD) at the baseline visit two weeks prior to cataract surgery. These metrics include tear break up time (TBUT), standard patient evaluation of eye dryness questionnaire (SPEED), ocular surface and surface disease index (OSDI) surveys, and lipid layer thickness (LLT). At the follow up visit four weeks after cataract surgery, these same metrics will be assessed again for any significant changes.

Eligibility Criteria:
Inclusion Criteria:

* Age greater than 18 at the time of informed consent
* Must understand; be willing and able, and likely to fully comply with study procedures, visit schedule, and restrictions
* Upcoming scheduled senile cataract surgery

Exclusion Criteria:

* Eyelid abnormalities
* Patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months
* Ocular surgery within the last 6 months
* Occlusion therapy with lacrimal or punctum plugs within the last 3 months
* Patients with an ocular surface abnormality that may compromise corneal integrity
* Patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months)
* Patients with cicatricial lid margin disease
* patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia
* Patients with permanent makeup or tattoos on their eyelids.
* Previous application/administration of Systane iLux or LipiFlow treatment
Immunotherapy in Eyelid Viral Papilloma

intralesional injection of Candida antigens for treating eyelid warts is supposed to have less destructive effect than other surgical interventions

Despite many surgical and interventional modalities of treating ocular warts, all have a destructive nature for this delicate tissue with a high recurrence rate. intralesional injection of Candida antigens was suggested to be an effective and safe treatment for such a condition aim: Providing safe and effective treatment of ocular wart. objective:

1. To determine the efficacy of intralesional injection of Candida antigens in the treatment of eyelids wart
2. To determine the safety of intralesional injection of Candida antigens in the treatment of eyelids wart
3. To report complications of intralesional injection of Candida antigens in the treatment of eyelids wart

Eligibility Criteria:
Inclusion Criteria:

* patients with cutaneous eyelid viral warts whether single or multiple, with no concurrent systemic or topical treatment for warts. Patients aged more than 12 years, with sensitivity test, showed induration less than or equal to five mm. and patients can understand and comply with the requirements of the trials.

Exclusion Criteria:

* pregnancy, breastfeeding, patients with immunodeficiency; like diabetics. In addition, patients with a history of hypersensitivity to any used component in this trial, asthma, or allergic skin diseases. Moreover, patients on any treatment modality for warts at least 1 month before the start of the study.
Hypoxia, Appetite, and Energy Intake in Young Female Adults

The goal of this clinical trial is to investigate the effects of acute passive continuous hypoxemia (simulated high-altitude at rest) on appetite and energy intake in healthy young female adults. The main questions it aims to answer are:

* Does six hours of simulated high-altitude (5000 meters) reduce scores of subjective appetite and energy intake?
* Do changes in appetite and energy intake persist in the hours following the end of hypoxic exposure? Researchers will compare the effects of simulated high-altitude to a control normoxia (sea-level) condition to see if exposure to low oxygen levels independently affect appetite and energy intake.

Participants will:

* Visit the laboratory for a preliminary screening session to assess eligibility.
* Undergo two randomized, single-blind, experimental sessions consisting of six hours of passive exposure to normoxia or hypoxia in a climate-controlled chamber.
* Consume foods provided from a curated list, served in ad libitum quantities, after leaving the laboratory to assess post-exposure energy intake.


Eligibility Criteria:
Inclusion Criteria:

* English or French speaking
* Ability to provide informed consent

Exclusion Criteria:

* History or evidence of chronic disease
* Current use of hypolipemic medication
* Current use of hormonal contraceptives
* Current use of antidepressants
* Current use of anticoagulants
* Ongoing smoking status
* Experiencing pregnancy, puerperium, or irregular menstrual cycles
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment.


Eligibility Criteria:
Key Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
2. Histologically confirmed Stage II or IIIA NSCLC
3. Measurable disease as assessed per RECIST v1.1
4. Confirm eligibility for an R0 resection with curative intent

Key Exclusion Criteria:

1. Any prior therapy for current lung cancer, including chemotherapy, or radiotherapy
2. Known Epidermal growth factor receptor (EGFR) mutation or Anaplastic Lymphoma Kinase (ALK) gene translocation
3. Any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days before randomization
4. Active autoimmune diseases or history of autoimmune diseases that may relapse
5. History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea

Obstructive sleep apnea results in decreased attentiveness and response times in patients. The objective of this study is to quantify these consequences in pediatric OSA patients using an already established tool for examining the results of sleep deprivation and fragmentation: psychomotor vigilance testing. PVT has been used in children, but has not been studied in pediatric OSA patients. This study aims to employ PVT along the normal course of diagnosis and treatment of pediatric OSA patients in our clinical practice at Arkansas Children's Hospital. The investigators hypothesize that pediatric OSA patients will exhibit decreased PVT scoring when compared to children without OSA, and that PVT can be used to diagnose and monitor treatment outcomes in these patients.


Eligibility Criteria:
Inclusion Criteria:

* Healthy pediatric patients ages 6-18 years old
* with symptoms of OSA (snoring, pauses in sleep breathing, restless sleep, frequent arousals, excellive daytime sleepiness, morning headaches)
* with physical exam findings consistent with adenotonsillar hypertrophy
* those identified as good candidates for adenotonsillectomy
* who are to undergo a polysomnogram as part of their preoperative work-up

Exclusion Criteria:

* History of attention deficit disorder, developmental delay, or mental retardation
* Children taking any neurotropic medications (including antiepileptics, antidepressives, and stimulants)
* Children previously treated for OSA (surgically or medically)
* Children with significant comorbidities including other sleep-related disorders
Finnish Telestroke Pilot 2007-2009

Objective is to describe two years experience from The Finnish Telestroke piloting between Helsinki University Central Hospital (HUCH), Department of Neurology, The Hub, and five hospitals, the spokes. The participating hospitals are from Rovaniemi (Lapland), Kemi (North-West of Finland), Lappeenranta, Kuusankoski and Kotka from South-East of Finland. All the participating hospitals have a stroke unit and the thrombolysis treatment and the follow up of the patients are carried in the treating hospital. The aim of the pilot is to provide these hospitals expertise in thrombolysis treatment during off-hours through teleconsultations.

The teleconsultations were begun between the participating hospitals 05/2007 after about 1 years preparation period. During the preparation period the staff from participating hospitals were trained with simulation training and lectures held by the local staff and the faculty of the Helsinki University hospital.

Telestroke consultation: During two way interactive audio-visual consultation the thrombolysis decision is based on: 1) the consultant going through a check up list of indications and no contraindications to the treatment together with the treating physician and 2) Clinical assessment of NIHSS by the treating physician under guidance of the consultant through the two way video system besides 3) Evaluation of the head CT scan.

The data registered is based on documents made at HUCH and the follow up data provided by the chief neurologist of the other hospitals. 109 teleconsultations have been documented over 2 years period. A unique feature of the Finnish pilot is the high percentage of consultations leading to thrombolysis treatment. Another special feature is that the consultant does the teleconsultation work besides other on call duties.


Eligibility Criteria:
Inclusion Criteria:

* All stroke patients inside 4.5 hours from the symptom onset considered as thrombolysis candidates by the treating physician of the spoke. In suspected basilar artery thrombosis up to 48 h from symptom onset.

Exclusion Criteria:

* Symptom onset \> 4.5 h